Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 103

    1.

    Key issues in the modes of action and effects of trichloroethylene metabolites for liver and kidney tumorigenesis.

    Caldwell JC, Keshava N.

    Environ Health Perspect. 2006 Sep;114(9):1457-63. Review.PMID: 16966105 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Key scientific issues in the health risk assessment of trichloroethylene.

    Chiu WA, Caldwell JC, Keshava N, Scott CS.

    Environ Health Perspect. 2006 Sep;114(9):1445-9. Review.PMID: 16966103 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    North American white mitochondrial haplogroups in prostate and renal cancer.

    Booker LM, Habermacher GM, Jessie BC, Sun QC, Baumann AK, Amin M, Lim SD, Fernandez-Golarz C, Lyles RH, Brown MD, Marshall FF, Petros JA.

    J Urol. 2006 Feb;175(2):468-72; discussion 472-3.PMID: 16406974 [PubMed - indexed for MEDLINE]Related articles

    4.

    Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.

    Liu K, Xu L, Berger JP, Macnaul KL, Zhou G, Doebber TW, Forrest MJ, Moller DE, Jones AB.

    J Med Chem. 2005 Apr 7;48(7):2262-5.PMID: 15801817 [PubMed - indexed for MEDLINE]Related articles

    5.

    Mitochondrial energy metabolism in heart failure: a question of balance.

    Huss JM, Kelly DP.

    J Clin Invest. 2005 Mar;115(3):547-55. Review.PMID: 15765136 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    mtDNA mutations increase tumorigenicity in prostate cancer.

    Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, Lim S, Issa MM, Flanders WD, Hosseini SH, Marshall FF, Wallace DC.

    Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24. Epub 2005 Jan 12.PMID: 15647368 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

    Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R.

    JAMA. 2004 Dec 1;292(21):2585-90. Epub 2004 Nov 22.PMID: 15572716 [PubMed - indexed for MEDLINE]Related articles

    8.

    G-protein signaling participates in the development of diabetic cardiomyopathy.

    Harris IS, Treskov I, Rowley MW, Heximer S, Kaltenbronn K, Finck BN, Gross RW, Kelly DP, Blumer KJ, Muslin AJ.

    Diabetes. 2004 Dec;53(12):3082-90.PMID: 15561937 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites.

    Sérée E, Villard PH, Pascussi JM, Pineau T, Maurel P, Nguyen QB, Fallone F, Martin PM, Champion S, Lacarelle B, Savouret JF, Barra Y.

    Gastroenterology. 2004 Nov;127(5):1436-45.PMID: 15521013 [PubMed - indexed for MEDLINE]Related articles

    11.

    Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis.

    Hays T, Rusyn I, Burns AM, Kennett MJ, Ward JM, Gonzalez FJ, Peters JM.

    Carcinogenesis. 2005 Jan;26(1):219-27. Epub 2004 Sep 24.PMID: 15447978 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Regulation of phase I and phase II steroid metabolism enzymes by PPAR alpha activators.

    Fan LQ, You L, Brown-Borg H, Brown S, Edwards RJ, Corton JC.

    Toxicology. 2004 Nov 15;204(2-3):109-21.PMID: 15388238 [PubMed - indexed for MEDLINE]Related articles

    13.

    Nuclear receptor signaling and cardiac energetics.

    Huss JM, Kelly DP.

    Circ Res. 2004 Sep 17;95(6):568-78. Review.PMID: 15375023 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Role of the peroxisome proliferator-activated receptor alpha (PPARalpha) in responses to trichloroethylene and metabolites, trichloroacetate and dichloroacetate in mouse liver.

    Laughter AR, Dunn CS, Swanson CL, Howroyd P, Cattley RC, Corton JC.

    Toxicology. 2004 Oct 15;203(1-3):83-98.PMID: 15363585 [PubMed - indexed for MEDLINE]Related articles

    15.

    Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome.

    Robitaille J, Brouillette C, Houde A, Lemieux S, Pérusse L, Tchernof A, Gaudet D, Vohl MC.

    J Hum Genet. 2004;49(9):482-9. Epub 2004 Aug 10.PMID: 15309680 [PubMed - indexed for MEDLINE]Related articles

    16.

    PPARalpha agonist-induced rodent tumors: modes of action and human relevance.

    Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM, Roberts RA, Fenner-Crisp PA.

    Crit Rev Toxicol. 2003;33(6):655-780. Review.PMID: 14727734 [PubMed - indexed for MEDLINE]Related articles

    17.

    Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation.

    Moller DE, Berger JP.

    Int J Obes Relat Metab Disord. 2003 Dec;27 Suppl 3:S17-21. Review.PMID: 14704738 [PubMed - indexed for MEDLINE]Related articles

    18.

    Bezafibrate induces a mitochondrial derangement in human cell lines: a PPAR-independent mechanism for a peroxisome proliferator.

    Scatena R, Bottoni P, Vincenzoni F, Messana I, Martorana GE, Nocca G, De Sole P, Maggiano N, Castagnola M, Giardina B.

    Chem Res Toxicol. 2003 Nov;16(11):1440-7.PMID: 14615970 [PubMed - indexed for MEDLINE]Related articles

    19.

    Stimulation of cardiac cardiolipin biosynthesis by PPARalpha activation.

    Jiang YJ, Lu B, Xu FY, Gartshore J, Taylor WA, Halayko AJ, Gonzalez FJ, Takasaki J, Choy PC, Hatch GM.

    J Lipid Res. 2004 Feb;45(2):244-52. Epub 2003 Nov 1.PMID: 14594999 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Trichloroethylene effects on gene expression during cardiac development.

    Collier JM, Selmin O, Johnson PD, Runyan RB.

    Birth Defects Res A Clin Mol Teratol. 2003 Jul;67(7):488-95.PMID: 14565619 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data